Hong Kong Stock Movement | GIANT BIOGENE (02367) Falls Over 3% Again, Share Price Hits New Low Since Listing; Citi Expects Full-Year Revenue Growth Target Difficult to Achieve

Stock News11-19

GIANT BIOGENE (02367) fell over 3% again, touching HK$18.4 intraday, a new low since its listing. As of press time, it was down 3.24% at HK$18.51, with a turnover of HK$56.3929 million.

On the news front, Citi released a research report stating that GIANT BIOGENE's online sales performance during the Double 11 promotion was weaker than expected. The bank lowered its profit forecasts by approximately 11% to 17%, cut its target price from HK$38.4 to HK$29.3, maintained a "Buy" rating, but initiated a 30-day negative catalyst watch.

The bank believes that management's target of 10% full-year revenue growth for 2026 will be difficult to achieve, and expects margin pressure to intensify amid a potential downturn in operating leverage. Additionally, on November 12, MSCI announced the results of its November 2026 quarterly index review, in which 38 stocks, including GIANT BIOGENE, were removed from the MSCI China Index. The adjustment will take effect after the close on November 30.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment